
Choksi Laboratories (CHOKSILA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
114.0M
Gross Profit
97.5M
85.53%
Operating Income
18.6M
16.35%
Net Income
9.2M
8.08%
Balance Sheet Metrics
Total Assets
653.3M
Total Liabilities
417.3M
Shareholders Equity
236.0M
Debt to Equity
1.77
Cash Flow Metrics
Revenue & Profitability Trend
Choksi Laboratories Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 417.8M | 367.0M | 344.4M | 300.4M | 256.9M |
Cost of Goods Sold | 71.9M | 37.2M | 33.8M | 28.3M | 35.1M |
Gross Profit | 345.9M | 329.7M | 310.6M | 272.1M | 221.8M |
Gross Margin % | 82.8% | 89.9% | 90.2% | 90.6% | 86.3% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 11.6M | 11.1M | 7.8M | 7.8M |
Other Operating Expenses | 63.8M | 63.2M | 56.9M | 50.3M | 51.1M |
Total Operating Expenses | 63.8M | 74.8M | 68.1M | 58.0M | 59.0M |
Operating Income | 48.0M | 47.2M | 49.5M | 36.6M | -3.0M |
Operating Margin % | 11.5% | 12.9% | 14.4% | 12.2% | -1.2% |
Non-Operating Items | |||||
Interest Income | - | 1.6M | 2.0M | 1.2M | 4.4M |
Interest Expense | 26.5M | 30.1M | 34.9M | 32.1M | 28.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 21.5M | 16.6M | 37.2M | 3.7M | -28.1M |
Income Tax | 6.3M | 5.5M | 5.1M | 1.6M | -2.0M |
Effective Tax Rate % | 29.3% | 33.3% | 13.7% | 43.6% | 0.0% |
Net Income | 15.2M | 11.1M | 32.1M | 2.1M | -26.1M |
Net Margin % | 3.6% | 3.0% | 9.3% | 0.7% | -10.2% |
Key Metrics | |||||
EBITDA | 113.0M | 105.4M | 106.4M | 91.8M | 47.0M |
EPS (Basic) | - | ₹1.59 | ₹4.61 | ₹0.30 | ₹-3.74 |
EPS (Diluted) | - | ₹1.59 | ₹4.61 | ₹0.30 | ₹-3.74 |
Basic Shares Outstanding | - | 6965000 | 6965000 | 6965000 | 6965000 |
Diluted Shares Outstanding | - | 6965000 | 6965000 | 6965000 | 6965000 |
Income Statement Trend
Choksi Laboratories Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 6.1M | 6.6M | 3.4M | 4.1M | 3.1M |
Short-term Investments | 1.2M | 4.3M | 4.2M | 662.0K | 576.0K |
Accounts Receivable | 112.7M | 103.9M | 106.5M | 102.9M | 81.6M |
Inventory | 5.6M | 3.6M | 2.1M | 2.5M | 1.1M |
Other Current Assets | 6.8M | 1.0K | 6.2M | -1.0K | -1.0K |
Total Current Assets | 163.2M | 145.7M | 139.5M | 140.1M | 130.3M |
Non-Current Assets | |||||
Property, Plant & Equipment | 471.3M | 36.1M | 36.1M | 36.1M | 36.1M |
Goodwill | 4.8M | 3.6M | 3.9M | 3.2M | 2.9M |
Intangible Assets | 4.8M | 3.6M | 3.9M | 3.2M | 2.9M |
Long-term Investments | - | 0 | 0 | - | - |
Other Non-Current Assets | 141.0K | 2.0K | 1.0K | 909.0K | 2 |
Total Non-Current Assets | 490.1M | 473.8M | 464.2M | 504.1M | 533.5M |
Total Assets | 653.3M | 619.5M | 603.6M | 644.2M | 663.8M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 54.3M | 39.3M | 18.0M | 40.2M | 48.3M |
Short-term Debt | 131.9M | 117.9M | 72.0M | 76.9M | 78.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 8.8M | 706.0K | 867.0K | 1.6M | 436.0K |
Total Current Liabilities | 238.8M | 188.5M | 125.1M | 155.2M | 162.2M |
Non-Current Liabilities | |||||
Long-term Debt | 159.6M | 190.8M | 252.1M | 296.0M | 313.5M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | - | -1.0K | -1.0K | - | - |
Total Non-Current Liabilities | 178.5M | 208.9M | 267.4M | 309.9M | 324.1M |
Total Liabilities | 417.3M | 397.4M | 392.6M | 465.1M | 486.3M |
Equity | |||||
Common Stock | 69.7M | 69.7M | 69.7M | 69.7M | 69.7M |
Retained Earnings | - | 135.3M | 124.2M | 92.2M | 90.1M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 236.0M | 222.1M | 211.1M | 179.0M | 177.5M |
Key Metrics | |||||
Total Debt | 291.6M | 308.7M | 324.2M | 372.9M | 391.5M |
Working Capital | -75.5M | -42.8M | 14.3M | -15.1M | -31.9M |
Balance Sheet Composition
Choksi Laboratories Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 21.5M | 16.6M | 37.2M | 3.7M | -28.1M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 3.9M | -8.4M | -12.5M | -18.0M | -4.0M |
Operating Cash Flow | 51.4M | 36.6M | 35.0M | 16.6M | -8.8M |
Investing Activities | |||||
Capital Expenditures | -74.4M | -69.1M | -7.1M | -26.4M | -80.5M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | 197.0K | 1.9M | 52.0K | - | - |
Investing Cash Flow | -74.2M | -67.2M | -7.0M | -26.4M | -80.5M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 38.4M | 310.1M | 20.0M | 26.7M | 47.3M |
Debt Repayment | -58.7M | -363.7M | -55.1M | -41.3M | -11.2M |
Financing Cash Flow | -10.5M | -11.1M | -36.6M | -14.5M | 36.1M |
Free Cash Flow | 40.9M | 44.6M | 41.0M | 50.1M | -22.0M |
Net Change in Cash | -33.3M | -41.8M | -8.6M | -24.3M | -53.2M |
Cash Flow Trend
Choksi Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
101.93
Price to Book
6.63
Price to Sales
3.69
Profitability Ratios
Profit Margin
3.52%
Operating Margin
10.90%
Return on Equity
6.45%
Return on Assets
2.33%
Financial Health
Current Ratio
0.68
Debt to Equity
123.52
Beta
0.16
Per Share Data
EPS (TTM)
₹2.20
Book Value per Share
₹33.82
Revenue per Share
₹60.82
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
choksila | 1.6B | 101.93 | 6.63 | 6.45% | 3.52% | 123.52 |
Dr. Lal PathLabs | 288.0B | 55.99 | 13.24 | 22.08% | 20.29% | 7.14 |
Syngene | 268.2B | 52.80 | 5.68 | 10.50% | 13.61% | 12.23 |
Vimta Labs | 31.5B | 44.49 | 8.30 | 17.78% | 19.93% | 2.25 |
Krsnaa Diagnostics | 26.8B | 33.93 | 3.02 | 8.79% | 10.84% | 23.06 |
Suraksha Diagnostic | 16.6B | 49.97 | 7.86 | 15.14% | 12.62% | 42.28 |
Financial data is updated regularly. All figures are in the company's reporting currency.